advertisement
Abstract #24763 Published in IGR 11-4
Brimonidine purite solution for open-angle glaucoma or ocular hypertension
Batiste CG; Myers J; Katz LJExpert Review of Ophthalmology 2008; 3: 513-515
Brimonidine (0.1 and 0.15%) tartrate used with the preservative purite has been shown to be as efficacious as brimonidine 0.2% tartrate in lowering intraocular pressure in clinical trials. The purite preservative has proven to be better tolerated and less toxic in brimonidine solution than the original preservative benzalkonium chloride. In addition, the lower concentrations of active drug appear to offer safer adverse event profiles than the original formulation, while maintaining its efficacy.
L.J. Katz. Glaucoma Service, Wills Eye Hospital, Thomas Jefferson Medical University, Philadelphia, PA 19107-5599, United States. ljkatz@willseye.org
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
